

UC Davis

UC Davis Previously Published Works

Title

APOE Effects on Late Life Cognitive Trajectories in Diverse Racial/Ethnic Groups

Permalink

<https://escholarship.org/uc/item/7p69s033>

Journal

Journal of the International Neuropsychological Society, 29(2)

ISSN

1355-6177

Authors

Chan, Michelle L
Meyer, Oanh L
Farias, Sarah T
[et al.](#)

Publication Date

2023-02-01

DOI

10.1017/s1355617722000030

Peer reviewed



Published in final edited form as:

J Int Neuropsychol Soc. 2023 February ; 29(2): 126–135. doi:10.1017/S1355617722000030.

APOE Effects on Late Life Cognitive Trajectories in Diverse Racial/Ethnic Groups

Michelle L. Chan, Ph.D.¹, Oanh L. Meyer, Ph.D.¹, Sarah T. Farias, Ph.D.¹, Rachel A. Whitmer, Ph.D.², Kumar Rajan, Ph.D.², John Olichney, MD¹, David Johnson, Ph.D.¹, Dan Mungas, Ph.D.¹

¹Department of Neurology, University of California, Davis

²Department of Public Health Sciences, University of California, Davis

Abstract

Objective.—This study evaluated: 1)APOE $\epsilon 4$ prevalence among Black, Latino, and White older adults, 2)associations of APOE $\epsilon 4$ status with baseline level and change over time of cognitive outcomes across groups, and 3)combined impact of APOE $\epsilon 4$ prevalence and magnitude of effect on cognitive decline within each racial/ethnic group.

Method.—Participants included 297 White, 138 Latino, 149 Black individuals from the longitudinal UC Davis Diversity Cohort who had APOE genotyping and 2 cognitive assessments. Magnitude of associations of $\epsilon 4$ with cognitive baseline and change across racial/ethnic groups was tested with multilevel parallel process longitudinal analyses and multiple group models.

Results.— $\epsilon 4$ prevalence in Black (46%) and White participants (46%) was almost double that of Latino participants (24%). $\epsilon 4$ was associated with poorer baseline episodic memory only in White participants ($p=0.001$), but had a moderately strong association with episodic memory change across all racial/ethnic groups (Blacks= -0.061 SD/year, Latinos= -0.055 , Whites= -0.055). $\epsilon 4$ association with semantic memory change was strongest in White participants (-0.071), intermediate in Latino participants (-0.041), and weakest in Black participants (-0.022).

Conclusion.—Calculated cognitive trajectories across racial/ethnic groups were influenced in an additive manner by $\epsilon 4$ prevalence and strength of association with cognitive decline within the group. Group differences in $\epsilon 4$ prevalences and associations of $\epsilon 4$ with cognition may suggest different pathways from APOE to cognitive decline, and, AD possibly having less salient impact on cognitive decline in non-White participants. Differential effects of APOE on episodic memory and non-memory cognition have important implications for understanding how APOE influences late life cognitive decline.

Keywords

Alzheimer's Disease; Cognition; Memory; Executive Functioning; Cognitive Aging; Neuropsychology

Introduction

Alzheimer's disease (AD) is a neurodegenerative condition that is associated with cognitive and functional decline. Evidence to date suggests that Black and Latino older adults are twice and 1.5 times as likely to have AD compared to White older adults (Alzheimer's Association, 2021; Tang et al., 2001). However, there are mixed findings on the rates of AD among Latino older adults with data showing higher risk in Latinos from the east coast (primarily Caribbean Hispanics), but not in Latinos from the west coast (primarily Mexican Americans) (Haan et al., 2007; Mehta & Yeo, 2017; Tang et al., 2001). It is important to understand factors that might contribute to racial/ethnic differences in AD. This includes biological factors as well as sociocultural factors including cultural differences and factors adversely impacting minority groups such as lower socioeconomic status, health inequalities, and less access to health care.

Although the apolipoprotein E $\epsilon 4$ (APOE $\epsilon 4$) allele is linked to increased risk of AD and cognitive decline, reported prevalence rates of the APOE $\epsilon 4$ allele across racial/ethnic groups varies across studies, though some studies suggest that there may be a higher prevalence of $\epsilon 4$ among Black older adults (Weuve et al., 2018) and lower prevalence among Latino older adults (Campos, Edland, & Peavy, 2013) compared to White older adults. Importantly, the effects of the APOE $\epsilon 4$ allele across racial/ethnic groups is not well understood at this time. Some studies report a weaker effect of APOE $\epsilon 4$ status on AD risk among Black and Latino groups compared to Whites older adults (Campos et al., 2013) while other studies have shown a similar effect (Tang et al., 1998; Weuve et al., 2018). There is also limited research on the influence of APOE $\epsilon 4$ on continuous measures of cognitive decline over time across racial/ethnic groups, although the limited data with Black individuals shows a similar pattern of decline in memory compared to White individuals (Barnes et al., 2013). While some studies report that $\epsilon 4$ is associated with higher risk of cognitive impairment and dementia among Latino individuals, these studies do not examine APOE $\epsilon 4$ effects on pattern of cognitive decline across domains of cognition in Latino older adults. It is important to delineate the effect of APOE $\epsilon 4$ on cognitive trajectories since decline is a more specific marker of brain disease and is less related to non-brain variables (e.g., education level, cultural background, sociodemographic factors, etc.) that can have strong associations with one time cognitive measurements. Furthermore, to understand the impact of APOE $\epsilon 4$ on cognition within a specific group, it is important that we consider both prevalence and magnitude of effect of $\epsilon 4$ within a group. Given the limited research and largely unknown effects of APOE $\epsilon 4$ on cognition among diverse groups, further research in this area is essential.

The goals of this study were to: 1) evaluate the prevalence of APOE $\epsilon 4$ among Black, Latino, and White older adults, 2) evaluate the differential effects across these groups of APOE $\epsilon 4$ status on baseline level and change over time of cognitive outcomes, and 3) evaluate the combined impact of prevalence of APOE $\epsilon 4$ and magnitude of its effect on cognitive decline within each racial/ethnic group. Examining both prevalence and effect size of APOE $\epsilon 4$ on cognitive decline is important for understanding differential risk for cognitive decline across racial/ethnic groups (i.e., overall impact of APOE $\epsilon 4$ within a group will likely be larger if the prevalence of $\epsilon 4$ is higher and the effect of $\epsilon 4$ is greater).

Methods

Participants

Participants were from the UC Davis Diversity Cohort, a longitudinal study that includes substantial numbers of self-identified Latino, Black, and non-Latino White older adults. This cohort is heterogeneous in race, ethnicity, educational and occupational attainment, and socioeconomic and cognitive status. Participants were recruited through 1) a community outreach and screening program designed to identify and recruit individuals with cognitive functioning representative of the community dwelling population in a six-county catchment area in the central Sacramento/San Joaquin valley and east San Francisco Bay area of Northern California, and 2) memory/dementia clinics (Hinton et al., 2010). All participants signed informed consent, and all human subject involvement was overseen by the institutional review board.

All participants received multidisciplinary diagnostic evaluations at baseline and at approximately annual intervals following the baseline evaluation. Baseline and follow-up evaluations followed the same protocol with a detailed medical history, physical and neurological exam, clinical neuropsychological assessment, routine dementia work-up laboratory tests (e.g., Vitamin B12, thyroid stimulating hormone (TSH), rapid plasma regain (RPR), etc.), and neuroimaging (1.5T or 3T structural brain MRI including T1 weighted, T2 weighted, and FLAIR images). A family member or other informant was interviewed to obtain information about cognitive and independent functioning. Clinical neuropsychological tests were different from the cognitive measures used in analyses in this study to estimate cognitive trajectories.

Diagnosis of cognitive syndrome (Normal, mild cognitive impairment (MCI), Dementia) and, for individuals with dementia, underlying etiology, was made in a multidisciplinary consensus conference following standardized criteria and methods. Dementia was diagnosed using DSM-III-R (American Psychiatric Association, 1987) criteria for dementia modified such that dementia could be diagnosed in the absence of memory impairment if there was significant impairment of two or more other cognitive domains. MCI was diagnosed according to standard clinical criteria and was further sub-typed into amnesic MCI or non-amnesic MCI, single or multiple-domain (Petersen, 2004; Morris, 2006). Normal cognitive function was diagnosed if there was no clinically significant cognitive impairment. All diagnoses were made blind to the neuropsychological tests that were analyzed in this study.

The study consisted of 584 participants with APOE genotype and two or more cognitive assessments. There was variability in the number of evaluations completed by each individual due to a rolling enrollment; however, all baseline cognitive assessments were standardized. There were 297 White (51%), 138 Latino (24%), and 149 Black (26%) participants; 74 Latino participants (13%) were tested in Spanish, and all others were tested in English. Sample characteristics are presented in Table 1.

Cognitive Assessment

The cognitive outcomes in this study were measures of episodic memory, semantic memory, executive function, and spatial ability derived from the Spanish and English

Neuropsychological Assessment Scales (SENAS). The SENAS has undergone extensive development (Mungas, Reed, Marshall, & Gonzalez., 2000; Mungas, Reed, Crane, Haan & Gonzalez, 2004) as a battery of cognitive tests relevant to cognitive aging (Carmichael et al., 2012; Early et al., 2013; Fletcher et al., 2018; Gavett et al., 2018; Mungas et al., 2018) that allow for valid comparisons across racial, ethnic, and linguistic groups (Brewster et al., 2014; Melrose et al., 2015; Mungas, Reed, Haan, Gonzales, 2005; Mungas, Reed, Farias, DeCarli, 2005; Mungas, Widaman, Reed & Farias., 2011; Mungas et al., 2010;).

Item response theory and confirmatory factor analysis methods were used to construct Spanish and English Neuropsychological Assessment Scales (SENAS) measures that are psychometrically matched across domains in terms of level of reliability across the ability continuum. Importantly, these measures do not have floor and ceiling effect and are normally distributed. The episodic memory score is derived from a multi-trial 15-item word-list-learning test (Mungas et al. 2004). The semantic memory measure is a composite of highly correlated verbal (object-naming) and nonverbal (picture association) tasks. The executive function composite is constructed from component tasks of category fluency (animals, fruits, vegetables), phonemic (letter) fluency, and working memory (digit-span backward, visual-span backward, list sorting). Spatial ability was measured using the SENAS Spatial Localization scale which assesses ability to perceive and reproduce two-dimensional spatial relationships that are increasingly complex. Language of test administration was determined by an algorithm that combined information regarding each participant's language preference in several specific contexts (e.g., conversing at home, listening to radio or television, conversing outside the home, preferred language for reading). Each domain was z-standardized using the full baseline sample mean and standard deviation (mean of 0 and standard deviation of 1, range = -4 to 4).

APOE Genotyping

Apolipoprotein E (APOE) genotyping was carried out using the LightCycler ApoE mutation detection kit (Roche Diagnostics, Indianapolis, IN). APOE ϵ 4 prevalence (carrier status) was based on absence or presence of 1 APOE ϵ 4 allele. Allele frequencies were also computed for each ethnoracial group and subgroup of interest.

Data Analysis

Measures and Data Processing—SENAS measures of episodic memory, semantic memory, executive function, and spatial ability were measures of longitudinal change in cognition. Each of these four cognitive variables was transformed using the Blom inverse normal rank order transformation (Blom, 1958) in order to normalize these variables and establish a common scale (mean=0, SD=1). Presence versus absence of the APOE ϵ 4 allele was the primary independent variable. Covariates included age at baseline evaluation, education, gender, recruitment source, loss of follow-up due to death, and loss to follow-up for other reasons.

Longitudinal Modeling of Cognitive Trajectories—Mixed effects, parallel process longitudinal analyses were performed using MPlus version 8.2 multilevel modeling (Muthen & Muthen, 1998). In the Within part of this model, each of the four cognitive outcomes

was regressed on time in study. This generated person-specific intercept (in reference to cognitive baseline) and linear slope (in reference to cognitive change) random effects for each outcome. These random effects then served as dependent variables in the Between part of the model.

We utilized multiple group models to evaluate racial/ethnic group similarities and differences in effects of APOE and covariates on cognitive baseline and change components. In multiple group analyses, models are estimated for each group and specific parameters, APOE $\epsilon 4$ effects for example, can either be constrained to be equal across groups or can be freely estimated within groups. Less constrained models are compared to nested, more constrained models to determine if fit is significantly better when the parameters of interest are allowed to differ across groups. The likelihood ratio test for nested models (Satorra & Bentler, 2001; Satorra & Bentler, 2010) was used to determine if freely estimating specific parameters across groups resulted in significantly better model fit to the data.

Results

Sample Characteristics

Sample characteristics are presented in Table 1, stratified by race/ethnicity group. About 57% of the sample were female participants. Black and Latino participants were more likely to be females but White participants were evenly divided among males and females ($\chi^2[2]=26.654, p=0.001$). Approximately two thirds of the sample were recruited from the community (69%). Recruitment source differed by race/ethnicity ($\chi^2[2]=77.789, p=0.001$), with White participants more likely to be clinic referrals. Average age was about 76 years and this differed across groups ($F[2,581]=11.975, p=0.001$) with Latino participants being about 3 years younger at the baseline assessment than Black and White participants. Average education was 13.1 years and differed across groups ($F[2,581]=120.216, p=0.001$), with Latino participants having substantially less education. Average number of cognitive assessments was 5.5 and did not differ across groups. Eighty-three percent had three or more assessments and 54.5% had five or more. The average time between assessments was 1.0 year.

About 15% were diagnosed with dementia at the first assessment, 35% had mild cognitive impairment (MCI), and 50% were cognitively normal. Diagnosis differed by race/ethnicity ($\chi^2[4]=41.851, p=0.001$) with Whites more likely to have a diagnosis of MCI and less likely to be cognitively normal. $\epsilon 4$ was significantly related to baseline diagnosis (X-squared = 21.214, $df = 2, p\text{-value} = 2.475e-05$). See Table 5.

Prevalence of one or more APOE $\epsilon 4$ differed across groups ($\chi^2[2]=21.631, p=0.001$); Latino participants had roughly half the $\epsilon 4$ prevalence (24%) of Black (46%) and White (46%) participants. In the entire sample, there are 23 $\epsilon 4$ homozygotes (2 Black, 2 Latino, and 19 White participants), with a much higher prevalence in White participants. White participants recruited through clinic had higher APOE $\epsilon 4$ prevalence than community recruits and this difference was not significant, but it approached significance ($\chi^2[1]=3.506, p=0.061$). $\epsilon 4$ prevalence did not differ by recruitment source for Black or Latino participants. Baseline cognitive test scores all differed across race/ethnicity groups (p 's < 0.001). For episodic

memory, Black participants had higher average baseline scores than White participants whose scores were higher than Latino participants. For semantic memory and executive function, the pattern was White > Black > Latino participants, and for spatial ability it was White > Black \approx Latino participants.

Covariate Effects

We first estimated whether covariate effects on the intercepts (cognitive baseline) and slopes (change) of the four cognitive outcomes differed across groups. The effects of loss to follow-up on cognitive baseline ($p=0.001$) and deceased status on cognitive change ($p=0.001$) significantly differed across groups and were allowed to differ across groups in subsequent models. None of the other covariates had significantly different effects on cognitive baseline or change (p 's > 0.25).

APOE Effects

APOE effects in the full, combined sample are presented in Table 2. APOE had robust associations with cognitive change but limited associations on baseline scores. Episodic memory, semantic memory, and executive function all declined faster in participants with $\epsilon 4$ allele and the magnitude of the APOE effects on change in these domains was very similar. Spatial ability change was also significantly related to APOE, but the magnitude of this effect was approximately half of that for the other three cognitive domains. Episodic memory baseline score was one-fourth standard deviation lower in those who were $\epsilon 4$ positive, but other baseline scores were not affected by APOE.

Table 3 shows freely estimated effects of APOE on cognitive trajectory components in the three racial/ethnic groups. For slopes, presence of $\epsilon 4$ allele was associated with faster decline of episodic memory and executive function in all three groups. $\epsilon 4$ was associated with faster semantic memory decline in Latino and White participants and was associated with spatial decline only in White participants. The $\epsilon 4$ effect on semantic memory significantly differed across groups ($p=0.042$) but $\epsilon 4$ effects did not differ across groups for episodic memory ($p=0.975$), executive function ($p=0.391$), or spatial ability ($p=0.28$). Pairwise comparisons performed to test differences in $\epsilon 4$ effects on semantic memory change (slope) showed that this effect was significantly larger for White participants in comparison with Black participants ($p=0.005$) but the Black participant-Latino participant ($p=0.295$) and Latino participant-White participant ($p=0.196$) differences were not significant.

APOE associations with cognitive baselines were less robust. $\epsilon 4$ was associated with a lower average baseline episodic memory in White participants and with a lower baseline executive function in Latino participants. Pairwise comparisons showed that the APOE effect on baseline episodic memory significantly differed only for Black participants compared with White participants ($p=0.001$). The $\epsilon 4$ effect on executive function did not significantly differ across the three groups ($p=0.587$).

Model predicted trajectories for $\epsilon 4$ positive and negative individuals within the three groups for two cognitive outcomes, episodic memory and semantic memory, are presented in Figure 1. This figure shows clear baseline differences in episodic memory between $\epsilon 4$ positive and $\epsilon 4$ negative White participants but smaller difference for Black and Latino participants,

and small APOE related differences in baseline semantic memory. Episodic memory change (slopes) for $\epsilon 4$ positive individuals are quite similar across racial/ethnic groups, as are the slopes for $\epsilon 4$ negative individuals. In contrast, there is progressively greater divergence of $\epsilon 4$ positive and $\epsilon 4$ negative trajectories over time across for semantic memory from Black participants to Latino participants to White participants.

Combined Effects of APOE $\epsilon 4$ Prevalence and Impact

Figure 2 shows how APOE $\epsilon 4$ prevalence and the impact of $\epsilon 4$ when present jointly contribute to cognitive trajectories. We used results from this study to calculate expected semantic memory trajectories for four hypothetical groups with varying $\epsilon 4$ prevalences and $\epsilon 4$ effect sizes: 1) no $\epsilon 4$, 2) low $\epsilon 4$ prevalence and moderate effect size, 3) high $\epsilon 4$ prevalence and moderate $\epsilon 4$ effect size, and 4) high $\epsilon 4$ prevalence and strong $\epsilon 4$ effect size.

This figure demonstrates several salient points. First, absence of $\epsilon 4$ (hypothetical group 1) is associated with relatively stable semantic memory over time. Second, semantic memory decline is greater when prevalence of $\epsilon 4$ within a group is non-zero (groups 2, 3, and 4 compared to group 1), and higher prevalence is associated with faster decline when the impact/ $\epsilon 4$ effect size is the same (group 2 versus group 3). Third, greater $\epsilon 4$ impact is also associated with faster decline when $\epsilon 4$ prevalence is the same (group 3 versus group 4). Overall, $\epsilon 4$ will have a minimal impact on late life cognition in a population if its prevalence is low and its impact when present is low. As prevalence and impact increase they have additive effects that jointly contribute to cognitive decline.

Secondary Analyses

We performed a secondary analysis in which baseline clinical diagnosis (cognitively normal versus MCI versus dementia) was added as a covariate to the primary multiple group model. The pattern of results was similar but APOE effects were attenuated (see Table 4). For White participants, APOE continued to be associated with changes in episodic memory, semantic memory, and executive function, and effect sizes for semantic memory (-0.055) and executive function (-0.059) were about 25% higher than for episodic memory (-0.046). The APOE effect on episodic memory in Black participants continued to be strong (-0.054), but APOE was not significantly related to decline in other cognitive domains for Black participants or to decline in any domain for Latino participants.

We also examined the effects of number of $\epsilon 4$ alleles in full sample analyses. The number of $\epsilon 4$ was robustly associated with cognitive decline, but the incremental impact of a second $\epsilon 4$ was statistically significant only for executive function. We did not have adequate cell sizes to look at effects of $\epsilon 4$ homozygosity within racial/ethnic groups, specifically Black and Latino participants. However, among White participants, a second $\epsilon 4$ allele had no incremental impact on episodic memory change, but had a clear and statistically significant impact on executive function. Having a second $\epsilon 4$ allele had an impact on semantic memory (i.e., increases the $\epsilon 4$ effect by 70%), but it was not statistically significant ($p=.27$). Interestingly, when examining the overall $\epsilon 4$ effect, it was substantially reduced when $\epsilon 4$ -4 cases were removed from the Black and Latino groups, whereas the effect for White participants remained as strong when $\epsilon 4$ -4 cases were removed. The reduced $\epsilon 4$ effect

in the Black and Latino groups after excluding $\epsilon 4$ -4 cases suggest that $\epsilon 4$ may have a strong dose-dependent relation with cognition, but the small number of homozygous $\epsilon 4$ in these groups makes it difficult to interpret these results.

Summary of Results

Latino participants had roughly half the prevalence of $\epsilon 4$ carriers (24%) compared to Black (46%) and White (46%) participants. APOE $\epsilon 4$ showed robust relations to cognitive change (slopes) in all four domains in the full sample, but was related only to baseline performance for episodic memory, and not to baseline performance in other domains. APOE $\epsilon 4$ had a strong and equal effect on episodic memory change across the three groups, but its effect on semantic memory change followed a graded pattern: White>Latino>Black. A similar graded pattern was observed for executive function change, but these differences were not significant. APOE $\epsilon 4$ had limited effects on cognitive baselines, and was significantly associated only with episodic memory in White participants and executive function in Latino participants. When controlling for baseline clinical diagnosis (cognitively normal versus MCI versus dementia), we still found a very similar pattern of results although APOE effects were attenuated. Cognitive trajectories were influenced in an additive manner both by $\epsilon 4$ prevalence for a group and its effect size within the group.

Discussion

Results showed a complex pattern of similarities and differences in the association of APOE $\epsilon 4$ with late life cognitive trajectories across Black, Latino, and White older adults. APOE $\epsilon 4$ had a strong and equivalent association with episodic memory decline in all three groups. Salient differences were that 1) APOE $\epsilon 4$ prevalence in Black and White participants was nearly double that of Latino participants, 2) $\epsilon 4$ had a larger association with semantic memory decline in White participants, 3) $\epsilon 4$ association with decline of non-episodic memory cognitive variables was smaller in Black participants, and 4) $\epsilon 4$ was related to baseline episodic memory only in White participants. Importantly, our findings do not seem to be explained by the groups differing in degree of cognitive impairment at baseline given that our sensitivity analysis controlled for baseline diagnosis. The main $\epsilon 4$ pathway to cognitive decline is through brain changes resulting from $\epsilon 4$ related diseases like AD and CVD. Controlling for diagnosis should effectively remove a substantial part of the disease mediated pathway from APOE to cognition, consequently resulting in smaller $\epsilon 4$ effects after adjusting for diagnosis.

The literature on racial/ethnic differences in the APOE association with cognitive decline has been largely confined to comparisons of White and Black groups and results have been mixed. Our findings that APOE $\epsilon 4$ is associated with cognitive decline in both Black and White participants is consistent with other studies comparing these two groups (Fillenbaum et al., 2001; Kaup et al., 2015; Knopman, Mosley, & Catellier, 2009; Rajan et al., 2019; Sawyer, Sachs-Ericsson, Preacher, & Blazer, 2009). Our finding that the APOE association with episodic memory decline was the same in Black and White participants, while APOE had a stronger association with non-episodic memory decline in White participants is consistent with Barnes et al. (2013).

Results of this study showing APOE associations with cognitive decline in Latino older adults are novel and address a major knowledge gap. Latino participants in this study had roughly half the $\epsilon 4$ prevalence of Black and White groups, consistent with other studies that have reported lower $\epsilon 4$ prevalence in Latino individuals, especially in those with native American genetic ancestry. As depicted in Figure 2, $\epsilon 4$ prevalence and $\epsilon 4$ impact both contribute to expectancies for cognitive decline. The implication of lower $\epsilon 4$ prevalence in Latino older adults is that APOE is a less salient part of the pathway to cognitive decline in Latino individuals regardless of whether APOE has a similar effect when present.

There were also racial/ethnic group differences in prevalence of homozygous $\epsilon 4$ carriers, which was higher in whites. Unfortunately, we could not systematically examine homozygous versus heterozygous $\epsilon 4$ effects in Black and Hispanic participants due to cell size issues. There is evidence that homozygosity could contribute to domain specific effects in White participants, that is, there was an incremental effect of a second allele on executive function, but not on episodic memory, with a possible, intermediate effect on semantic memory (not reaching statistical significance).

Cognitive decline is multiply determined, and social cultural factors may modify the impact of biological factors like APOE. Results of this study raise questions about whether pathways from APOE to cognitive decline differ by race and ethnicity. APOE is a well-known risk factor for AD but is also a risk factor for vascular disease (Haan & Mayeda, 2010) and perhaps other non-AD disease processes, and so can affect cognition through both AD and non-AD pathways. It is relevant to distinguish between episodic memory and non-memory cognitive abilities because episodic memory is strongly and selectively influenced by damage to a limbic, medial temporal circuit involving structures including the hippocampus and entorhinal cortex, whereas non-memory cognitive abilities are more dependent on neocortical structures and circuits. See Figure 3 for conceptual model of AD and non-AD pathways from APOE to cognitive decline. Relevant questions underlying racial/ethnic differences in APOE effects on cognition include: 1) Is APOE differentially related to AD and non-AD pathologies across ethnoracial groups? 2) Are AD and non-AD differentially related to cognitive decline in different groups, and 3) Do AD and non-AD pathways differentially impact specific cognitive domains across groups?

This study did not measure underlying disease states and so cannot directly address questions about whether APOE is differentially related to AD across groups. Some previous studies on Black-White group disparities show equal risk for AD in these groups in $\epsilon 4$ positives but 2-4 times increased risk for AD in Black individuals for $\epsilon 4$ negatives (Tang et al., 1998; Weuve et al., 2018), and a meta-analysis identified a stronger association of APOE with AD in White individuals (Farrer et al., 1997). Collectively, these studies suggest that $\epsilon 4$ is less salient for AD risk in Black individuals, and conversely, that non-APOE factors are more important. A recent biomarker study showed lower CSF Tau and p-Tau levels in $\epsilon 4$ positive Black participants in comparison with $\epsilon 4$ positive White participants (Morris et al., 2019), which may possibly reflect a differential effect of APOE $\epsilon 4$ on underlying AD mechanisms (i.e., molecular biomarkers) with a weaker link between APOE and AD mechanisms in Black individuals. Our finding of lower prevalence of $\epsilon 4$ in Latino participants also suggests that APOE is less salient for cognitive decline in this group and

that the APOE to AD pathway is less important than in White participants. Finally, although APOE $\epsilon 4$ is linked to increased risk of AD and cognitive decline, not all older adults with AD have APOE $\epsilon 4$ alleles, highlighting the importance of understanding other sociocultural and biological variables that impact late-life cognitive health.

One hypothesis to explain our results is that AD is more strongly linked to APOE in White participants so that AD pathology is more advanced, on average, in $\epsilon 4$ positive White participants than in Black and Latino participants. There is a large body of evidence that AD selectively affects episodic memory early in the disease course when neurofibrillary pathology is confined to the medial temporal lobes, and then impacts non-memory cognition when pathology spreads to neocortex (Nelson, Braak, & Markesbery, 2009). Differential impact of the APOE to AD to cognition pathway could explain the group differences in effects of APOE on non-memory cognition in this study, but the equal effects on episodic memory would imply that non-AD pathways to episodic memory are more salient in the minority groups. APOE also is associated with vascular disease (Schilling et al., 2013), and previous studies have shown that APOE $\epsilon 4$ can modify the effects of cerebrovascular disease on cognitive outcomes and dementia risk. Memory impairment is most often associated with medial temporal lobe neurodegeneration in the elderly, but can also result from white matter disease affecting the uncinate and inferior longitudinal fasciculi (Lockhart et al., 2012).

This study has important limitations. First, the sample is essentially a sample of convenience. While there was considerable effort to recruit a sample that is representative of the respective communities in northern California (Hinton et al., 2010), it is important to evaluate the generalizability of our findings to other samples and other methods. Our sample of Latino participants was predominantly of Mexican and Central American origin, and may well not represent other Latino subgroups who have different cultural and genetic ancestry backgrounds. Additionally, clinical recruits, who were more likely to have MCI, constituted a larger percentage of White participants in our sample. Thus, our sample of White participants may not necessarily represent the general White population in the United States and could effectively enrich the White group for clinically apparent cognitive decline and presence of AD pathology. While this could contribute to greater average cognitive decline in White participants, it wouldn't explain a stronger association of APOE with decline of non-episodic memory abilities in white participants nor the equivalent APOE effect across groups on episodic memory decline. Second, the sample size is relatively small for evaluating what essentially are race/ethnicity by APOE $\epsilon 4$ interaction effects. The lack of statistically significant differences across racial/ethnic groups in APOE effects on executive function change may reflect limitations of statistical power. Third, sample size limitations precluded us from examining specific combinations of APOE alleles among these groups. These limitations suggest a need for replication within different, larger, representative samples that include Latino participants from different backgrounds. It is important for future, larger studies to address $\epsilon 4$ dose effects that couldn't be examined in this study. Additional limitations include the use of dated diagnostic criteria, and lack of robust data regarding dementia etiology.

This study also has strengths. It addresses a major knowledge gap by comparing APOE effects in three well characterized racial/ethnic groups. The study sample was heterogenous

with respect to APOE genotype, clinical characteristics, and cognitive trajectories. This heterogeneity facilitates finding relevant associations with cognitive decline. We measured cognitive decline across multiple domains using psychometrically matched measures on the SENAS which were carefully constructed to avoid floor and ceiling effects (Mungas et al., 2004). There was considerable longitudinal follow-up that enabled separation of APOE effects on baseline cognition from effects on longitudinal change.

Further research is needed to clarify the mechanisms by which APOE affects disease processes and ultimately late life cognitive decline in diverse older persons. Studies that directly measure disease biomarkers along with cognitive trajectories in large and representative samples of racially/ethnically diverse older adults are particularly relevant to answering questions about how racial/ethnic diversity influences cognitive decline and dementia. A better understanding of the complex pathways underlying cognitive decline is important not only for understanding dementia in these specific groups but also for elaborating the multiple, complex determinants of cognitive decline and dementia that transcend racial and ethnic differences.

Acknowledgements

We would like to acknowledge the devotion of the participants in this study who volunteered their time for comprehensive annual evaluations and repeated MRI scans. Many staff of the UC Davis Alzheimer's Disease Center made this study a reality. Esther Lara supervised all aspects of study implementation from participant recruitment through retention over time leading to successful longitudinal follow-up. This work was supported by multiple grants from the National Institute on Aging (NIA) (P30 AG10129, R01 AG021028, and R01 AG047827, C DeCarli, PI; R01 AG10220, D Mungas, PI; R01/RF1 AG031563, B Reed/D Mungas, PI; R01 AG031252, S Tomaszewski Farias, PI). No conflict of interest.

References

- Alzheimer's Association. (2021). Alzheimer's Disease Facts and Figures. *Alzheimer's and Dementia*, 17(3) 327–406.
- American Psychiatric Association. (1987). *Diagnostic and Statistical Manual of Mental Disorders* (3rd ed., revised)
- Barnes LL, Arvanitakis Z, Yu L, Kelly J, De Jager PL, & Bennett DA (2013). Apolipoprotein E and change in episodic memory in blacks and whites. *Neuroepidemiology*, 40(3), 211–219. 10.1159/000342778 [PubMed: 23364031]
- Blom G (1958). Statistical estimates and transformed beta-variables. *Biometrical Journal*, 3(4): 285–285. 10.1002/bimj.19610030410
- Brewster PW, Melrose RJ, Marquine MJ, Johnson JK, Napoles A, MacKay-Brandt A, Farias S, Reed B, & Mungas D (2014). Life experience and demographic influences on cognitive function in older adults. *Neuropsychology*, 28(6), 846–858. 10.1037/neu0000098 [PubMed: 24933483]
- Campos M, Edland SD, & Peavy GM (2013). Exploratory study of apolipoprotein E ϵ 4 genotype and risk of Alzheimer's disease in Mexican Hispanics. *Journal of the American Geriatrics Society*, 61(6), 1038–1040. 10.1111/jgs.12292 [PubMed: 23772735]
- Carmichael O, Mungas D, Beckett L, Harvey D, Tomaszewski Farias S, Reed B, Olichney J, Miller J, & Decarli C (2012). MRI predictors of cognitive change in a diverse and carefully characterized elderly population. *Neurobiology of aging*, 33(1), 83–95. 10.1016/j.neurobiolaging.2010.01.021 [PubMed: 20359776]
- Early DR, Widaman KF, Harvey D, Beckett L, Park LQ, Farias ST, Reed BR, Decarli C, & Mungas D (2013). Demographic predictors of cognitive change in ethnically diverse older persons. *Psychology and aging*, 28(3), 633–645. 10.1037/a0031645 [PubMed: 23437898]

- Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, & van Duijn CM (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*, 278(16), 1349–1356. [PubMed: 9343467]
- Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, & Launer LJ (2001). The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. *Journal of the American Geriatrics Society*, 49(9), 1148–1155. 10.1046/j.1532-5415.2001.49230.x [PubMed: 11559372]
- Fletcher E, Gavett B, Harvey D, Farias ST, Olichney J, Beckett L, DeCarli C, & Mungas D (2018). Brain volume change and cognitive trajectories in aging. *Neuropsychology*, 32(4), 436–449. 10.1037/neu0000447 [PubMed: 29494196]
- Gavett BE, Fletcher E, Harvey D, Farias ST, Olichney J, Beckett L, DeCarli C, & Mungas D (2018). Ethnoracial differences in brain structure change and cognitive change. *Neuropsychology*, 32(5), 529–540. 10.1037/neu0000452 [PubMed: 29648842]
- Haan MN, & Mayeda ER (2010). Apolipoprotein E Genotype and Cardiovascular Diseases in the Elderly. *Current cardiovascular risk reports*, 4(5), 361–368. 10.1007/s12170-010-0118-4 [PubMed: 20694037]
- Haan MN, Miller JW, Aiello AE, Whitmer RA, Jagust WJ, Mungas DM, Allen LH, & Green R (2007). Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. *The American journal of clinical nutrition*, 85(2), 511–517. 10.1093/ajcn/85.2.511 [PubMed: 17284751]
- Hinton L, Carter K, Reed BR, Beckett L, Lara E, DeCarli C, & Mungas D (2010). Recruitment of a community-based cohort for research on diversity and risk of dementia. *Alzheimer disease and associated disorders*, 24(3), 234–241. 10.1097/WAD.0b013e3181c1ee01 [PubMed: 20625273]
- Kaup AR, Nettiksimmons J, Harris TB, Sink KM, Satterfield S, Metti AL, Ayonayon HN, Yaffe K, & Health, Aging, and Body Composition (Health ABC) Study (2015). Cognitive resilience to apolipoprotein E ε4: contributing factors in black and white older adults. *JAMA neurology*, 72(3), 340–348. 10.1001/jamaneurol.2014.3978 [PubMed: 25599330]
- Knopman DS, Mosley TH, Catellier DJ, & Coker LH (2009). Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 5(3), 207–214. 10.1016/j.jalz.2009.01.027
- Lockhart SN, Mayda AB, Roach AE, Fletcher E, Carmichael O, Maillard P, Schwarz CG, Yonelinas AP, Ranganath C, & Decarli C (2012). Episodic memory function is associated with multiple measures of white matter integrity in cognitive aging. *Frontiers in human neuroscience*, 6, 56. 10.3389/fnhum.2012.00056 [PubMed: 22438841]
- Mehta KM, & Yeo GW (2017). Systematic review of dementia prevalence and incidence in United States race/ethnic populations. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 13(1), 72–83. 10.1016/j.jalz.2016.06.2360
- Melrose RJ, Brewster P, Marquine MJ, MacKay-Brandt A, Reed B, Farias ST, & Mungas D (2015). Early life development in a multiethnic sample and the relation to late life cognition. *The journals of gerontology. Series B, Psychological sciences and social sciences*, 70(4), 519–531. 10.1093/geronb/gbt126 [PubMed: 24389122]
- Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger T, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, & Xiong C (2019). Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. *JAMA neurology*, 76(3), 264–273. 10.1001/jamaneurol.2018.4249 [PubMed: 30615028]
- Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, & Kukull WA (2006). The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. *Alzheimer disease and associated disorders*, 20(4), 210–216. 10.1097/01.wad.0000213865.09806.92 [PubMed: 17132964]
- Mungas D, Beckett L, Harvey D, Farias ST, Reed B, Carmichael O, Olichney J, Miller J, & DeCarli C (2010). Heterogeneity of cognitive trajectories in diverse older persons. *Psychology and aging*, 25(3), 606–619. 10.1037/a0019502 [PubMed: 20677882]

- Mungas D, Gavett B, Fletcher E, Farias ST, DeCarli C, & Reed B (2018). Education amplifies brain atrophy effect on cognitive decline: implications for cognitive reserve. *Neurobiology of aging*, 68, 142–150. 10.1016/j.neurobiolaging.2018.04.002 [PubMed: 29798764]
- Mungas D, Reed BR, Crane PK, Haan MN, & González H (2004). Spanish and English Neuropsychological Assessment Scales (SENAS): further development and psychometric characteristics. *Psychological assessment*, 16(4), 347–359. 10.1037/1040-3590.16.4.347 [PubMed: 15584794]
- Mungas D, Reed BR, Farias S, & DeCarli C (2005). Criterion-referenced validity of a neuropsychological test battery: equivalent performance in elderly Hispanics and non-Hispanic Whites. *Journal of the International Neuropsychological Society : JINS*, 11(5), 620–630. 10.1017/S1355617705050745 [PubMed: 16212690]
- Mungas D, Reed BR, Haan MN, & González H (2005). Spanish and English neuropsychological assessment scales: relationship to demographics, language, cognition, and independent function. *Neuropsychology*, 19(4), 466–475. 10.1037/0894-4105.19.4.466 [PubMed: 16060821]
- Mungas D, Reed BR, Marshall SC, & Gonzalez HM (2000). Development of psychometrically matched English and Spanish language neuropsychological tests for older persons. *Neuropsychology*, 14(2), 209–223. 10.1037//0894-4105.14.2.209 [PubMed: 10791861]
- Mungas D, Widaman KF, Reed BR, & Tomaszewski Farias S (2011). Measurement invariance of neuropsychological tests in diverse older persons. *Neuropsychology*, 25(2), 260–269. 10.1037/a0021090 [PubMed: 21381830]
- Muthen L & Muthen B (1998). *Mplus User's Guide*.
- Nelson PT, Braak H, & Markesbery WR (2009). Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. *Journal of neuropathology and experimental neurology*, 68(1), 1–14. 10.1097/NEN.0b013e3181919a48 [PubMed: 19104448]
- Petersen RC (2004). Mild cognitive impairment as diagnostic entity. *Journal of internal medicine*, 256(3), 183–194. 10.1111/j.1365-2796.2004.0133.x [PubMed: 15324362]
- Rajan KB, Barnes LL, Wilson RS, Weuve J, McAninch EA, & Evans DA (2019). Apolipoprotein E Genotypes, Age, Race, and Cognitive Decline in a Population Sample. *Journal of the American Geriatrics Society*, 67(4), 734–740. 10.1111/jgs.15727 [PubMed: 30584655]
- Satorra A, & Bentler PM (2001). A scaled difference chi-square test statistic for moment structure analysis. *Psychometrika*, 66(4), 507–514. 10.1007/BF02296192
- Satorra A, & Bentler PM (2010). Ensuring Positiveness of the Scaled Difference Chi-square Test Statistic. *Psychometrika*, 75(2), 243–248. 10.1007/s11336-009-9135y [PubMed: 20640194]
- Sawyer K, Sachs-Ericsson N, Preacher KJ, & Blazer DG (2009). Racial differences in the influence of the APOE epsilon 4 allele on cognitive decline in a sample of community-dwelling older adults. *Gerontology*, 55(1), 32–40. 10.1159/000137666 [PubMed: 18525196]
- Schilling S, DeStefano AL, Sachdev PS, Choi SH, Mather KA, DeCarli CD, Wen W, Høgh P, Raz N, Au R, Beiser A, Wolf PA, Romero JR, Zhu YC, Lunetta KL, Farrer L, Dufouil C, Kuller LH, Mazoyer B, Seshadri S, ... Debette S (2013). APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. *Neurology*, 81(3), 292–300. 10.1212/WNL.0b013e31829bfda4 [PubMed: 23858411]
- Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, & Mayeux R (2001). Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. *Neurology*, 56(1), 49–56. 10.1212/wnl.56.1.49 [PubMed: 11148235]
- Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B, & Mayeux R (1998). The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. *JAMA*, 279(10), 751–755. 10.1001/jama.279.10.751 [PubMed: 9508150]
- Weuve J, Barnes LL, Mendes de Leon CF, Rajan KB, Beck T, Aggarwal NT, Hebert LE, Bennett DA, Wilson RS, & Evans DA (2018). Cognitive Aging in Black and White Americans: Cognition, Cognitive Decline, and Incidence of Alzheimer Disease Dementia. *Epidemiology (Cambridge, Mass.)*, 29(1), 151–159. 10.1097/EDE.0000000000000747 [PubMed: 28863046]




Figure 1.
 Trajectories of Episodic Memory and Semantic Memory by APOE $\epsilon 4$ Status and Race/
 Ethnicity - APOE Effects Freely Estimated




Figure 2.

Trajectories of semantic memory by APOE $\epsilon 4$ prevalence and $\epsilon 4$ effect size. Modest APOE effect is effect observed in single group model (semantic memory slope = -0.053 , intercept = -0.027). Strong effect is effect observed for Whites in multiple group model: slope = -0.071 , intercept = -0.150 . Prevalences correspond to observed prevalences for Latino (0.24) and White (0.46) groups.

Note. We used the estimated semantic memory intercepts and slopes for $\epsilon 4$ negative and $\epsilon 4$ positive individuals from the single group, combined sample model along with results from the multiple group analysis to derive expected semantic memory trajectories for four hypothetical groups: 1) no $\epsilon 4$ - based on the semantic memory intercept and slope for the no $\epsilon 4$ group in the single group model, 2) low $\epsilon 4$ prevalence (24% - equivalent to that observed in Latino group) and moderate $\epsilon 4$ impact (-0.053 SD/year - effect observed in the single group model), 3) high $\epsilon 4$ prevalence (46% - equivalent to that observed in Black and White groups) and moderate $\epsilon 4$ impact (-0.053 SD/year), and 4) high $\epsilon 4$ prevalence and strong $\epsilon 4$ impact (-0.071 SD/year - observed effect for Whites in multiple group model).




Figure 3. Conceptual model of AD and non-AD pathways from APOE to cognitive decline.

Table 1.

Sample characteristics.

	BL(N=149)	LA(N=138)	WH(N=297)	Total
Gender - Female	107 (71.8%)	84 (60.9%)	139 (46.8%)	330 (56.5%)
Age (baseline) - Mean (SD)	76.2 (± 7.0)	73.2 (± 6.6)	76.7 (± 7.3)	75.7 (± 7.2)
Education - Mean (SD)	13.4 (± 3.3)	8.8 (± 5.4)	14.9 (± 3.1)	13.1 (± 4.5)
Recruitment Source - Community	130 (87.2%)	118(85.5%)	158 (53.2%)	406 (69.5%)
APOE $\epsilon 4$ alleles - Full Sample - 1+	69 (46.3%)	33 (23.9%)	137 (46.1%)	239 (40.9%)
APOE $\epsilon 4$ alleles - Community - 1+	61 (46.9%)	28 (23.9%)	63 (40.9%)	152 (37.9%)
APOE $\epsilon 4$ alleles - Clinic - 1+	8 (42.1%)	5 (25.0%)	73 (52.5%)	86 (48.3%)
Diagnosis (Baseline) - Dementia	19 (13.5%)	26 (20.8%)	39 (13.3%)	84 (15.0%)
Diagnosis (Baseline) - MCI	40 (28.4%)	20 (16.0%)	137 (46.8%)	197 (35.2%)
Diagnosis (Baseline) - Normal	82 (58.2%)	79 (63.2%)	117 (39.9%)	278 (49.7%)
Number of Assessments - Mean (SD)	5.4 (± 2.8)	6.0 (± 3.2)	5.3 (± 3.0)	5.5 (± 3.0)
Episodic Memory Baseline - Mean (SD)	0.2 (± 0.8)	-0.2 (± 0.9)	0.0 (± 0.9)	0.0 (± 0.9)
Semantic Memory Baseline - Mean (SD)	-0.2 (± 0.7)	-0.7 (± 0.9)	0.4 (± 0.8)	0.0 (± 0.9)
Executive Function Baseline - Mean (SD)	0.0 (± 0.8)	-0.3 (± 0.9)	0.3 (± 0.9)	0.1 (± 0.9)
Spatial Baseline - Mean (SD)	-0.3 (± 0.9)	-0.4 (± 1.1)	0.4 (± 0.9)	0.0 (± 1.0)

(BL = Black, LA = Latino, WH = non-Latino White)

Variables that differed significantly by race/ethnicity include: gender, recruitment source, baseline age, education, diagnosis, prevalence of one or more APOE $\epsilon 4$ allele, and all baseline cognitive scores.

Table 2.

APOE effects on cognitive baseline (intercepts) and change (slopes) in the full sample combining Blacks, Latinos, and Whites participants.

Cognitive Trajectory Component	estimate	s.e.	p
Episodic Memory Baseline	-0.268	0.063	0.000
Semantic Memory Baseline	-0.027	0.065	0.674
Executive Function Baseline	-0.112	0.066	0.086
Spatial Ability Baseline	-0.097	0.073	0.184
Episodic Memory Change	-0.057	0.012	0.000
Semantic Memory Change	-0.053	0.010	0.000
Executive Function Change	-0.062	0.013	0.000
Spatial Ability Change	-0.029	0.013	0.020

Note: Tabled values are unstandardized regression weights (β s) with standard errors and p-levels. Results show estimates of APOE variable effects of 1 APOE ϵ 4 allele versus 0 ϵ 4 alleles on cognitive intercepts and slopes by racial/ethnic group. Estimates are SD units of cognitive composite scores.

⁺
=p<.05,

⁺⁺
=p<.015,

⁺⁺⁺
=p<.001

Table 3.

APOE effects on cognitive baseline (intercepts) and change (slopes) by racial/ethnic group. Results show effects of presence of 1 APOE ϵ 4 allele versus 0 ϵ 4 alleles.

Cognitive Trajectory Component	BL estimate (s.e)	LA estimate (s.e)	WH estimate (s.e)
Episodic Memory Baseline	-0.128 (0.100)	-0.247 (0.143)	-0.436 (0.092) ⁺⁺⁺
Semantic Memory Baseline	-0.078 (0.112)	-0.080 (0.129)	-0.150 (0.085)
Executive Function Baseline	-0.082 (0.115)	-0.256 (0.117) ⁺	-0.154 (0.098)
Spatial Ability Baseline	-0.044 (0.129)	-0.264 (0.180)	-0.157 (0.101)
Episodic Memory Change	-0.061 (0.020) ⁺⁺	-0.055 (0.028) ⁺	-0.055 (0.019) ⁺⁺
Semantic Memory Change	-0.022 (0.013)	-0.041 (0.015) ⁺⁺	-0.071 (0.018) ⁺⁺⁺
Executive Function Change	-0.035 (0.017) ⁺	-0.050 (0.026) ⁺	-0.076 (0.021) ⁺⁺⁺
Spatial Ability Change	0.004 (0.019)	-0.034 (0.023)	-0.043 (0.020) ⁺

BL = Black, LA = Latino, WH = non-Latino White

Note: Tabled values are unstandardized regression weights (β s) with standard errors and p-levels. Results show estimates of APOE variable effects of 1 APOE ϵ 4 allele versus 0 ϵ 4 alleles on cognitive intercepts and slopes by racial/ethnic group. Estimates are SD units of cognitive composite scores.

⁺ = p < .05,

⁺⁺ = p < .015,

⁺⁺⁺ = p < .001

Table 4.

APOE effects on cognitive baseline (intercepts) and change (slopes) by racial/ethnic group, adjusting for clinical diagnosis as a covariate. Results show effects of presence of 1 APOE ϵ 4 allele versus 0 ϵ 4 alleles.

Cognitive Trajectory Component	BL estimate (s.e)	LA estimate (s.e)	WH estimate (s.e)
Episodic Memory Baseline	-0.021 (0.092)	0.020 (0.123)	-0.226 (0.073) ⁺⁺
Semantic Memory Baseline	-0.005 (0.095)	0.115 (0.119)	-0.027 (0.080)
Executive Function Baseline	0.015 (0.103)	-0.076 (0.122)	-0.001 (0.088)
Spatial Ability Baseline	0.062 (0.113)	-0.064 (0.164)	-0.047 (0.097)
Episodic Memory Change	-0.054 (0.019) ⁺⁺	-0.037 (0.027)	-0.046 (0.019) ⁺
Semantic Memory Change	-0.011 (0.012)	-0.022 (0.013)	-0.055 (0.017) ⁺⁺
Executive Function Change	-0.030 (0.016)	-0.034 (0.023)	-0.059 (0.021) ⁺⁺
Spatial Ability Change	0.004 (0.018)	-0.025 (0.020)	-0.032 (0.019)

BL = Black, LA = Latino, WH = non-Latino White,

⁺=p<.05,

⁺⁺=p<.015,

⁺⁺⁺=p<.001

Table 5.

APOE status and cognitive diagnosis

	Absence of $\epsilon 4$ Allele	Presence of 1 $\epsilon 4$ Allele
Dementia	35	49
Mild Cognitive Impairment	104	93
Cognitively Normal	187	91

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript